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respectively (P< .05 vs placebo). CONCLUSIONS: These findings suggest that PHEN/
TPM ER-enhanced WL is associated with a reduction in annual medication costs vs 
placebo in patients with MetS.
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OBJECTIVES: Immunobiologicals (IMB) should only be used as a second line treatment 
of rheumatic diseases because of its potential risks and high cost. This study aimed 
to outline the profile of IMB use by the analyses of pharmacotherapeutic and phar-
macoeconomic indicators derived from a cohort of rheumatic patients. METHODS: 
This was a prospective observational exploratory study that analyzed data from the 
follow-up charts of 204 patients in treatment with IMB, previously authorized by rheu-
matologists and then monitored by a Pharmaceutical Auditing Clinical Management 
Program of a Health Insurance Provider in Fortaleza, Brazil, from March-2012 to 
September-2014. For the pharmacotherapeutic and economic analysis, the follow-
ing indicators were used: “Most used IMB” “ indication of the IMB therapy”, “route of 
administration” and “direct cost”. For calculation of the costs, the electronic source 
Brasíndice was used. RESULTS: The most common indications for IMB use were 
rheumatoid arthritis 46.57 % (95/204) and ankylosing spondylitis 41.67% (85/204). 
The intravenous route (IV) was more frequent, 63 % (158/251), when compared to the 
subcutaneous (SC), 37 % (93/251). The main IV IMB was infliximab, 37.27 % (81/251). 
The most used SC IMB and higher proportional increase prescriptive was adalimumab 
15.94% (40/251). The IMB with higher direct cost was infliximab, U$ 41,147.52 per 
capita. The cumulative global cost the immunobiological therapy during the period 
of study was U$6,366,673.33 as adjusted by weight. CONCLUSIONS: Monitoring of 
patients using IMB through a multidisciplinary team is an important clinical manage-
ment tool, enabling the development of strategies for the rationalization of future 
interventions and reduction of its high cost.
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OBJECTIVES: To quantify the clinical and economic benefits of weight loss among 
obese adults in the U.S. and how benefits vary across subsets of the obese popula-
tion. METHODS: A validated, Markov-based microsimulation model was used to sim-
ulate 10-year health and economic outcomes for different subsets of the obese adult 
population, with sample populations drawn from the 2005-2012 National Health and 
Nutrition Examination Surveys. Obese subgroups included those with prediabetes; 
ages 20-44, 45-64, and 65 and above; and obese category I, II, and III cohorts. Prediction 
equations for disease onset and economic outcomes come from published literature 
and original research. The model predicts direct and indirect economic outcomes 
from payer, employer, and societal perspectives. RESULTS: The present value (3% 
discount rate) of simulated medical savings associated with modest 5% weight among 
obese adults averaged $9,100 cumulative over 10 years. Obese adults age 65 and older 
and obese adults with prediabetes experienced the most medical savings—averaging 
$20,550 and $14,110, respectively, over 10 years. Simulated medical benefits among 
these cohorts came from reduced onset of cardiovascular disease, diabetes, and other 
chronic conditions associated with obesity. Subgroups with the lowest savings from 
5% weight loss were the age 20-44 and category I obese groups, averaging $5,800 and 
$7,290, respectively, over 10 years. Weight loss resulted in the largest reduction in dia-
betes incidence in the obese with prediabetes and obese age 20-44 populations, with 
10-year incidence reductions of 19% and 16%, respectively. CONCLUSIONS: Intensive 
lifestyle intervention and other weight loss programs often exceed 5% weight loss, 
generating sizeable medical savings that vary by patient characteristics. Study results 
underscore the importance of reducing excess body weight to prevent new onset of 
disease, and help identify target populations to maximize the medical savings and 
other benefits of weight loss.
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OBJECTIVES: Opioid induced constipation (OIC) is the most common, persistent 
and debilitating side effect reported in patients receiving opioids to manage pain. 
Laxatives are commonly prescribed to treat OIC but in some patients they provide 
inadequate response. Movantik is a peripherally acting mu-opioid receptor antago-
nist used to treat patients with inadequate response to laxative(s) (LIR). A cost effec-
tiveness model was constructed from the UK payer perspective to compare Movantik 
25mg with placebo, rescue laxatives, Relistor and Targin in LIR patients. METHODS: 
Two Phase III 12-week placebo-controlled RCTs, KODIAC 4 and 5, provided data on 
response rates, transition probabilities and EQ-5D inputs for the model for Movantik, 
placebo and rescue laxatives. Tolerability data in the model is generated from both 
these studies and KODIAC 8, a 52-week safety study. The model comprises a decision 
tree for the first 4 weeks of treatment, followed by a Markov model with a 4-week 
cycle length and the following states: non-OIC on treatment, OIC, non-OIC not on 
treatment and death. A mixed treatment comparison provides data on OIC status 
for Relistor and Targin. Resource utilization data used in the model were gathered 
from a UK-based burden of illness study and physician surveys. RESULTS: Movantik 
has an ICER of £10,849 vs. placebo, of £12,639 vs. placebo & rescue laxatives and is 
dominant vs Relistor over a 5 year time horizon in LIR patients. The probabilistic 
OBJECTIVES: To determine healthcare costs among immediate release (IR) hydroco-
done patients diagnosed with opioid abuse compared to those without such diagno-
sis in the United States (US). METHODS: Retrospective analysis using claims from 
the Truven MarketScan® commercial, Medicare supplemental, and Medicaid data-
bases was performed. Patients prescribed IR hydrocodone during the 6-month base-
line period (7/2011-12/2011), and with continuous enrollment during baseline and 
the 12-month follow-up period (2012), were selected. IR hydrocodone patients with 
an ICD-9-CM diagnosis for opioid abuse or dependence (abuse) were identified in 
the follow-up period. Descriptive analyses were employed to compare demographic 
and clinical characteristics between diagnosed opioid abusers and non-abusers. 
Total healthcare costs (standardized to 2013 US dollars) for abusers vs. non-abusers 
during the follow-up were estimated by plan type. Propensity score matching was 
used to estimate incremental costs in the follow-up. RESULTS: A total of 1,743,933 
commercial, 277,096 Medicare, and 157,992 Medicaid IR hydrocodone patients were 
selected. Prevalence of diagnosed opioid abuse for these samples in follow-up was 
0.9%, 0.5%, and 3.2% for commercial, Medicare, and Medicaid, respectively. Among 
commercial patients, unmatched data at baseline showed that abusers had on aver-
age higher co-morbidity burden (0.96 vs. 0.67), and higher pill count (60.8 vs. 20.5 
pills/month) and days’ supply (67.4 vs. 24.1 days) for IR hydrocodone, compared to 
non-abusers. After matching there were no differences in co-morbidity burden (.96 
vs. .99) and pill count (60.8 vs. 60.5) but days’ supply remained significantly different 
(67.4 vs. 63.4). In the matched subset, incremental costs were significantly higher 
among abusers ($14,720, $6,589, and $14,786 for commercial, Medicare, and Medicaid 
patients, respectively) as compared with non-abusers. CONCLUSIONS: IR hydroco-
done patients with diagnosed opioid abuse have higher healthcare costs when com-
pared to matched non-abusers, suggesting significant negative economic impact 
of opioid abuse in the US. Similar trends were observed regardless of plan type.
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OBJECTIVES: Studies have estimated the cost of biologics needed to achieve an addi-
tional responder as measured by Psoriasis Area and Severity Index (PASI) 75and PASI 
90; however, limited information is available including PASI 100. The purpose of this 
analysis was to evaluate the cost per additional responder associated with biologics 
for PASI 75, PASI 90 and PASI 100. METHODS: A literature review was conducted to 
identify randomized controlled trials and meta-analyses that included informa-
tion on PASI 75, PASI 90 or PASI 100 and associated number needed to treat (NNT) 
compared to placebo for adalimumab (ADA), etanercept (ETN), infliximab (IFX), and 
ustekinumab (UST). NNT was calculated as the inverse of absolute risk reduction 
from placebo. The Wholesale Acquisition Costs for each biologic incurred during 
12 weeks of treatment from initiation were determined using Analy$ource® data 
as of November 2014. Administration costs were not included. Cost per additional 
responder was calculated as the NNT multiplied by 12 week drug costs. RESULTS: 
Cost per additional responder for PASI 75 was lowest for ADA ($18,065 - $18,647) 
and IFX ($18,101 - $19,493) followed by UST 45mg ($23,903 - $24,516), ETN ($37,825 
- $41,036), and UST 90mg ($45,048 - $48,418). Cost per additional responder for PASI 
90 was lowest for ADA ($26,805 – $30,418) and IFX ($27,569 - $30,632) followed by UST 
45mg ($38,765 - $39,532), UST 90mg ($71,095 - $88,256) and ETN ($84,749 - $89,209). 
Limited data were available on PASI 100; however, cost per additional responder was 
found to be higher than PASI 75 and PASI 90 based on available data. CONCLUSIONS: 
Cost per additional responder was higher for PASI 90 and PASI 100 given the greater 
NNT for each measure respectively. Understanding the association between costs 
and NNT across various levels of efficacy may be valuable for decision makers when 
evaluating multiple medications.
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OBJECTIVES: Higher healthcare costs are incurred by patients with MetS. WL may 
decrease the risk of MetS and its component comorbidities, thereby reducing medi-
cation use. PHEN/TPM ER treatment, combined with lifestyle interventions, can 
induce WL and reduce incidence of MetS. This post-hoc analysis of a PHEN/TPM ER 
study evaluated annual cost-offsets associated with changes in concomitant medi-
cation use among patients with MetS. METHODS: CONQUER randomized obese/
overweight patients (BMI ≥ 27 -≤ 45kg/m2) with ≥ 2 weight-related comorbidities to 
placebo (n= 994), PHEN 7.5mg/TPM ER 46mg (7.5/46; n= 498), or PHEN 15mg/TPM ER 
92mg (15/92; n= 995). MetS was defined as presence of ≥ 3 of the following risk fac-
tors: waist circumference ≥ 102cm (men), ≥ 88cm (women); triglycerides ≥ 150mg/dL; 
HDL-cholesterol < 40mg/dL (men), < 50mgl/dL (women); systolic blood pressure (BP) 
≥ 130mmHg or diastolic BP ≥ 85mmHg; and fasting glucose ≥ 100mg/dL. This analysis 
included patients with MetS using ≥ 1 concomitant medication at baseline or end of 
treatment (EOT) for hypertension, dyslipidemia, or type 2 diabetes. Cost-offsets (±SD) 
in antihypertensive, lipid-lowering, and antidiabetic medication use were calculated 
by multiplying unit cost (Medi-Span’s PriceRx) by number of doses per day from 
baseline to Week 56/EOT. PHEN/TPM ER cost was not included. RESULTS: In total, 349 
patients receiving placebo, 184 receiving 7.5/46, and 359 receiving 15/92, had MetS at 
baseline and received ≥ 1 concomitant medication. At baseline, mean weight (±SD) 
was 105±18kg among all patients. Baseline annual concomitant medication costs 
were $1222±1450, $1306±1401, and $1303±1348 for placebo, 7.5/46, and 15/92, respec-
tively. At EOT, mean percent WL was -1.9%, -8.6%, and -10.5%, respectively (P< .0001 
vs placebo). At EOT, annual concomitant medication costs increased with placebo 
and decreased with PHEN/TPM ER: $36±33 (+3%), -$83±46 (-6%), and -$103±33 (-8%), 
